Overview:
This randomized, placebo-controlled clinical trial assessed whether adding oxymetazoline to intranasal corticosteroid therapy (mometasone furoate nasal spray, or MFNS) would enhance treatment outcomes in patients with nasal polyposis. The study evaluated symptom scores, airflow, mucociliary clearance, and polyp size over a 6-week period with twice-daily use.
The Takeaways:
-
The oxymetazoline + MFNS group showed significantly greater improvement in:
-
Blocked nose
-
Hyposmia (reduced sense of smell)
-
Nasal mucociliary clearance time (NMCC)
-
Total nasal polyp score
compared to the placebo + MFNS group after 6 weeks. -
There was no significant improvement in peak inspiratory flow in the oxymetazoline group compared to placebo.
-
No evidence of rebound congestion was found after 4 weeks of oxymetazoline use.
Why It Matters:
This study suggests that, in nasal polyposis, adding oxymetazoline to a corticosteroid regimen can offer additional clinical benefits beyond steroid use alone.. It also demonstrates safety without rebound congestion, supporting its use in therapy for nasal polyposis.
The Link to Allermi:
Allermi’s data-driven approach to nasal treatment includes the use of oxymetazoline combined with intranasal corticosteroid. The results of this study reinforce Allermi’s strategy of combining oxymetazoline with corticosteroid, particularly when addressing nasal polyposis, while also reinforcing the lack of rebound congestion even with long-term, twice daily use.
For more details, refer to the full study: Does oxymetazoline increase the efficacy of nasal steroids in treating nasal polyposis?
